Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$23.22
-0.79-3.29%
At close: -
$23.23
0.010.04%
After Hours: 5:24 PM EDT
Comments
Loading...
Beam Therapeutics Analyst Ratings and Price Targets | NASDAQ:BEAM | Benzinga
Beam Therapeutics Inc has a consensus price target of $55.74 based on the ratings of 20 analysts. The high is $113 issued by SVB Leerink on August 10, 2022. The low is $26 issued by RBC Capital on February 26, 2025. The 3 most-recent analyst ratings were released by Scotiabank, Jones Trading, and HC Wainwright & Co. on March 10, 2025, respectively. With an average price target of $51.33 between Scotiabank, Jones Trading, and HC Wainwright & Co., there's an implied 120.98% upside for Beam Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
Jones Trading
HC Wainwright & Co.
Guggenheim
RBC Capital
1calculated from analyst ratings
Analyst Ratings for Beam Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/12/2025 | Buy Now | — | Cantor Fitzgerald | Rick Bienkowski27% | — | Reiterates | Overweight → Overweight | Get Alert |
| 03/10/2025 | Buy Now | 72.19% | Scotiabank | Greg Harrison51% | → $40 | Upgrade | Sector Perform → Sector Outperform | Get Alert |
| 03/10/2025 | Buy Now | 46.36% | Jones Trading | Soumit Roy46% | → $34 | Upgrade | Hold → Buy | Get Alert |
| 03/10/2025 | Buy Now | 244.38% | HC Wainwright & Co. | Patrick Trucchio47% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 03/03/2025 | Buy Now | 7.62% | Scotiabank | Greg Harrison51% | $24 → $25 | Maintains | Sector Perform | Get Alert |
| 02/28/2025 | Buy Now | 244.38% | HC Wainwright & Co. | Patrick Trucchio47% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 235.77% | Guggenheim | Debjit Chattopadhyay54% | $78 → $78 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2025 | Buy Now | 11.92% | RBC Capital | Luca Issi42% | $24 → $26 | Maintains | Sector Perform | Get Alert |
| 02/03/2025 | Buy Now | 244.38% | HC Wainwright & Co. | Patrick Trucchio47% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 01/29/2025 | Buy Now | — | Cantor Fitzgerald | Rick Bienkowski27% | — | Upgrade | Neutral → Overweight | Get Alert |
| 12/09/2024 | Buy Now | 244.38% | HC Wainwright & Co. | Patrick Trucchio47% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2024 | Buy Now | 244.38% | HC Wainwright & Co. | Patrick Trucchio47% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 11/06/2024 | Buy Now | 3.31% | RBC Capital | Luca Issi42% | $27 → $24 | Maintains | Sector Perform | Get Alert |
| 11/06/2024 | Buy Now | 67.89% | Leerink Partners | Rick Bienkowski27% | $27 → $39 | Upgrade | Market Perform → Outperform | Get Alert |
| 10/16/2024 | Buy Now | 3.31% | Scotiabank | Greg Harrison51% | → $24 | Initiates | → Sector Perform | Get Alert |
| 09/19/2024 | Buy Now | 16.23% | RBC Capital | Luca Issi42% | $27 → $27 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 09/17/2024 | Buy Now | — | Jones Trading | Soumit Roy46% | — | Initiates | → Hold | Get Alert |
| 09/11/2024 | Buy Now | 197.03% | Stifel | Benjamin Burnett46% | $66 → $69 | Maintains | Buy | Get Alert |
| 08/22/2024 | Buy Now | 244.38% | HC Wainwright & Co. | Patrick Trucchio47% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 106.63% | JP Morgan | Eric Joseph48% | $45 → $48 | Maintains | Overweight | Get Alert |
| 08/07/2024 | Buy Now | 33.45% | Barclays | Gena Wang49% | $33 → $31 | Maintains | Equal-Weight | Get Alert |
| 08/07/2024 | Buy Now | 16.23% | RBC Capital | Luca Issi42% | $27 → $27 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 07/23/2024 | Buy Now | 244.38% | HC Wainwright & Co. | Patrick Trucchio47% | → $80 | Initiates | → Buy | Get Alert |
| 05/08/2024 | Buy Now | 42.06% | Barclays | Gena Wang49% | $42 → $33 | Maintains | Equal-Weight | Get Alert |
| 04/23/2024 | Buy Now | 145.37% | Wedbush | David Nierengarten48% | $57 → $57 | Reiterates | Outperform → Outperform | Get Alert |
| 03/27/2024 | Buy Now | 145.37% | BMO Capital | Kostas Biliouris34% | → $57 | Maintains | Outperform | Get Alert |
| 02/28/2024 | Buy Now | 80.8% | Barclays | Gena Wang49% | $26 → $42 | Maintains | Equal-Weight | Get Alert |
| 02/28/2024 | Buy Now | 50.67% | RBC Capital | Luca Issi42% | $27 → $35 | Maintains | Sector Perform | Get Alert |
| 01/29/2024 | Buy Now | 72.19% | JP Morgan | Eric Joseph48% | $38 → $40 | Upgrade | Neutral → Overweight | Get Alert |
| 12/15/2023 | Buy Now | 50.67% | B of A Securities | Greg Harrison51% | → $35 | Downgrade | Buy → Neutral | Get Alert |
| 12/08/2023 | Buy Now | 29.14% | Jefferies | Michael Yee56% | $75 → $30 | Downgrade | Buy → Hold | Get Alert |
| 10/17/2023 | Buy Now | 37.75% | Cantor Fitzgerald | Rick Bienkowski27% | $56 → $32 | Maintains | Overweight | Get Alert |
| 09/13/2023 | Buy Now | 141.07% | Cantor Fitzgerald | Rick Bienkowski27% | → $56 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | Buy Now | 141.07% | Cantor Fitzgerald | Rick Bienkowski27% | → $56 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | Buy Now | 50.67% | Barclays | Gena Wang49% | $41 → $35 | Maintains | Equal-Weight | Get Alert |
| 08/09/2023 | Buy Now | 102.32% | Credit Suisse | Richard Law46% | $46 → $47 | Maintains | Neutral | Get Alert |
| 08/09/2023 | Buy Now | 141.07% | Citigroup | Samantha Semenkow33% | $60 → $56 | Maintains | Buy | Get Alert |
| 05/11/2023 | Buy Now | 80.8% | RBC Capital | Luca Issi42% | $50 → $42 | Maintains | Sector Perform | Get Alert |
| 05/11/2023 | Buy Now | 76.5% | Barclays | Gena Wang49% | $45 → $41 | Maintains | Equal-Weight | Get Alert |
| 05/11/2023 | Buy Now | 158.29% | Citigroup | Samantha Semenkow33% | $62 → $60 | Maintains | Buy | Get Alert |
| 03/21/2023 | Buy Now | 59.28% | Bernstein | William Pickering44% | → $37 | Initiates | → Market Perform | Get Alert |
| 03/01/2023 | Buy Now | 352% | Wells Fargo | Yanan Zhu35% | $125 → $105 | Maintains | Overweight | Get Alert |
| 02/01/2023 | Buy Now | 166.9% | Cantor Fitzgerald | Rick Bienkowski27% | → $62 | Initiates | → Overweight | Get Alert |
| 01/23/2023 | Buy Now | 231.47% | SVB Leerink | Mani Foroohar45% | $81 → $77 | Maintains | Outperform | Get Alert |
| 12/20/2022 | Buy Now | 184.12% | BMO Capital | Kostas Biliouris34% | $61 → $66 | Upgrade | Market Perform → Outperform | Get Alert |
| 12/13/2022 | Buy Now | 166.9% | Citigroup | Samantha Semenkow33% | → $62 | Initiates | → Buy | Get Alert |
| 11/08/2022 | Buy Now | 128.15% | Credit Suisse | Richard Law46% | $65 → $53 | Maintains | Neutral | Get Alert |
| 11/07/2022 | Buy Now | 248.69% | SVB Leerink | Mani Foroohar45% | $82 → $81 | Maintains | Outperform | Get Alert |
| 08/10/2022 | Buy Now | 158.29% | Barclays | Gena Wang49% | $38 → $60 | Maintains | Equal-Weight | Get Alert |
| 08/10/2022 | Buy Now | 386.44% | SVB Leerink | Rick Bienkowski27% | $118 → $113 | Maintains | Outperform | Get Alert |
| 06/17/2022 | Buy Now | 76.5% | BMO Capital | Kostas Biliouris34% | → $41 | Initiates | → Market Perform | Get Alert |
| 05/09/2022 | Buy Now | 420.88% | SVB Leerink | Rick Bienkowski27% | $118 → $121 | Maintains | Outperform | Get Alert |
| 04/28/2022 | Buy Now | 166.9% | Credit Suisse | Richard Law46% | → $62 | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for Beam Therapeutics (BEAM) stock?
The latest price target for Beam Therapeutics (NASDAQ:BEAM) was reported by Cantor Fitzgerald on March 12, 2025. The analyst firm set a price target for $0.00 expecting BEAM to fall to within 12 months (a possible -100.00% downside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Beam Therapeutics (BEAM)?
The latest analyst rating for Beam Therapeutics (NASDAQ:BEAM) was provided by Cantor Fitzgerald, and Beam Therapeutics reiterated their overweight rating.
When was the last upgrade for Beam Therapeutics (BEAM)?
The last upgrade for Beam Therapeutics Inc happened on March 10, 2025 when Scotiabank raised their price target to $40. Scotiabank previously had a sector perform for Beam Therapeutics Inc.
When was the last downgrade for Beam Therapeutics (BEAM)?
The last downgrade for Beam Therapeutics Inc happened on December 15, 2023 when B of A Securities changed their price target from N/A to $35 for Beam Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Beam Therapeutics (BEAM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on March 12, 2025 so you should expect the next rating to be made available sometime around March 12, 2026.
Is the Analyst Rating Beam Therapeutics (BEAM) correct?
While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a reiterated with a price target of $0.00 to $0.00. The current price Beam Therapeutics (BEAM) is trading at is $23.23, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.